(asco)

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCOActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…

4 weeks ago
Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study ExperienceMedidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience

Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience

New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials SINGAPORE, June…

1 month ago